Literature DB >> 19679011

Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.

Waleed Alduaij1, Tim M Illidge.   

Abstract

The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Early-phase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19679011     DOI： 10.1007/s11912-009-0049-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  36 in total

1.  A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

Authors:  Robert M Sharkey; Oliver W Press; David M Goldenberg
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

Review 2.  Radiolabeled antibody therapy of B-cell lymphomas.

Authors:  O W Press
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

3.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

Authors:  O W Press; J F Eary; T Gooley; A K Gopal; S Liu; J G Rajendran; D G Maloney; S Petersdorf; S A Bush; L D Durack; P J Martin; D R Fisher; B Wood; J W Borrow; B Porter; J P Smith; D C Matthews; F R Appelbaum; I D Bernstein
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

4.  Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Authors:  Thomas E Witzig; Christine A White; Leo I Gordon; Gregory A Wiseman; Christos Emmanouilides; James L Murray; John Lister; Pratik S Multani
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors:  Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

7.  Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.

Authors:  Samuel A Jacobs; Steven H Swerdlow; Jeffrey Kant; Kenneth A Foon; Rachel Jankowitz; Stephanie R Land; Nicholas DeMonaco; Judith Joyce; Jennifer L Osborn; Terry L Evans; Patricia M Schaefer; The Minh Luong
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Authors:  Amrita Krishnan; Auayporn Nademanee; Henry C Fung; Andrew A Raubitschek; Arturo Molina; Dave Yamauchi; Roberto Rodriguez; Ricardo T Spielberger; Peter Falk; Joycelynne M Palmer; Stephen J Forman
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

9.  Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Jane N Winter; David J Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W Rademaker; Bing Bing Weitner; Stephanie F Williams; Martin S Tallman; Ivana Micallef; Jayesh Mehta; Seema Singhal; Andrew M Evens; Michael Zimmer; Arturo Molina; Christine A White; Leo I Gordon
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 10.  The radioresponsiveness of human tumours and the initial slope of the cell survival curve.

Authors:  J Deacon; M J Peckham; G G Steel
Journal:  Radiother Oncol       Date:  1984-12       Impact factor: 6.280
View more
  2 in total

Review 1.  Cancer radioimmunotherapy.

Authors:  Robert M Sharkey; David M Goldenberg
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

2.  Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.

Authors:  Ekaterina Dadachova; Scott G Kitchen; Gregory Bristol; Gayle Cocita Baldwin; Ekaterina Revskaya; Cyril Empig; George B Thornton; Miroslaw K Gorny; Susan Zolla-Pazner; Arturo Casadevall
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.